ArticleOncology letters2025
Elective arteriovenous fistula ligation for prevention of lymphedema in a patient with breast cancer before ipsilateral axillary lymph node dissection: A case report.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Upper limb lymphedema (LE) may occur following radical treatment of breast cancer (BC), and may manifest more severely in patients with dialysis vascular access located on the ipsilateral limb. The present study reports a case of a 44-year-old female patient with patent arteriovenous fistula (AVF) in the left antecubital fossa following a third kidney transplant and the diagnosis of luminal B-like (human epidermal growth factor receptor 2-positive) BC of the left breast (clinical stage cT4bN2aM0), admitted to the Clinical Hospital of the Medical University of Silesia in Katowice (Poland) in October 2020. The patient received neoadjuvant systemic therapy, achieving partial regression of the tumor. Before a left-sided mastectomy with axillary lymph node dissection (ALND), the AVF was ligated. Following radiotherapy, trastuzumab treatment was continued for 18 cycles, along with hormonal therapy, and no upper limb LE developed. After 18 months, numerous metastases of the same biological subtype appeared in the area of the previously irradiated mastectomy scar. Palliative treatment was implemented and resulted in a complete objective response. First-line systemic treatment resulted in a partial response and disease control for 9 months. As of March 2025, the kidney graft function was stable (estimated glomerular filtration rate, 56.9 ml/min/1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.